Back to available technologies

Targeting the Wnt-beta-catenin Signaling Pathway to Augment the Efficacy of Checkpoint Inhibitor Immunotherapy

This technology is associated with theuse of Wnt-Beta cateniin antagonists to circumvent resistance and enhance the efficacy of currently available immune checkpoint inhibitors in patients with advanced cancer.

Duke File (IDF) Number

T-004723

Inventor(s)

  • Hanks, Brent
  • Holtzhausen, Alisha

For more information please contact

College

School of Medicine (SOM)

Interested in this Technology?

Submit your interest below.